Table 2. Adjuvant systemic therapy.
Number | (%) | ||
Endocrine therapy [n = 140] | Tamoxifen ± LH-RH agonist | 48 | (34%) |
Aromatase inhibitor | 75 | (54%) | |
Tamoxifen ± LH-RH agonist → Aromatase inhibitor | 15 | (10%) | |
Aromatase inhibitor → Tamoxifen | 1 | (1%) | |
Toremifene citrate | 1 | (1%) | |
Chemotherapy [n = 24] | Anthracyclin | 19 | (79%) |
Anthracyclin + Taxane | 5 | (21%) |
LH-RH, luteinizing hormone-releasing hormone.